Ultragenyx Pharmaceutical Beheer
Beheer criteriumcontroles 2/4
De CEO Ultragenyx Pharmaceutical is Emil Kakkis, benoemd in Apr2010, heeft een ambtstermijn van 14.58 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 13.08M, bestaande uit 6.3% salaris en 93.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 2.91% van de aandelen van het bedrijf, ter waarde $ 126.84M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 8.9 jaar en 8.6 jaar.
Belangrijke informatie
Emil Kakkis
Algemeen directeur
US$13.1m
Totale compensatie
| Percentage CEO-salaris | 6.3% |
| Dienstverband CEO | 14.6yrs |
| Eigendom CEO | 2.9% |
| Management gemiddelde ambtstermijn | 8.9yrs |
| Gemiddelde ambtstermijn bestuur | 8.6yrs |
Recente managementupdates
Recent updates
Ultragenyx: Ready For More Growth After Q3 Earnings Beat
Nov 12Ultragenyx: Excellent Company, Lackluster Stock
Nov 06We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt
Sep 04
Ultragenyx's Strong Pipeline And Valuation Concerns: A Balanced Perspective
Aug 22There's Reason For Concern Over Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Massive 26% Price Jump
Aug 03Shareholders Will Probably Hold Off On Increasing Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) CEO Compensation For The Time Being
Jun 12Ultragenyx: Modest Sales Growth, With Multiple Inflection Points Approaching
Jun 06We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt
May 24Ultragenyx Pharmaceutical Earnings: No Visible Path To Financial Success Yet
Mar 09Will Ultragenyx Pharmaceutical (NASDAQ:RARE) Spend Its Cash Wisely?
Feb 01There's No Escaping Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Muted Revenues Despite A 28% Share Price Rise
Dec 28Is There An Opportunity With Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) 47% Undervaluation?
Sep 12An Intrinsic Calculation For Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Suggests It's 50% Undervalued
May 24Improved Revenues Required Before Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Find Their Feet
Apr 17Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Could Be 33% Below Their Intrinsic Value Estimate
Feb 18Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$559m |
| Jun 30 2024 | n/a | n/a | -US$585m |
| Mar 31 2024 | n/a | n/a | -US$613m |
| Dec 31 2023 | US$13m | US$824k | -US$607m |
| Sep 30 2023 | n/a | n/a | -US$635m |
| Jun 30 2023 | n/a | n/a | -US$721m |
| Mar 31 2023 | n/a | n/a | -US$719m |
| Dec 31 2022 | US$12m | US$796k | -US$707m |
| Sep 30 2022 | n/a | n/a | -US$678m |
| Jun 30 2022 | n/a | n/a | -US$506m |
| Mar 31 2022 | n/a | n/a | -US$470m |
| Dec 31 2021 | US$10m | US$769k | -US$454m |
| Sep 30 2021 | n/a | n/a | -US$356m |
| Jun 30 2021 | n/a | n/a | -US$351m |
| Mar 31 2021 | n/a | n/a | -US$204m |
| Dec 31 2020 | US$5m | US$759k | -US$187m |
| Sep 30 2020 | n/a | n/a | -US$256m |
| Jun 30 2020 | n/a | n/a | -US$301m |
| Mar 31 2020 | n/a | n/a | -US$425m |
| Dec 31 2019 | US$7m | US$714k | -US$403m |
| Sep 30 2019 | n/a | n/a | -US$397m |
| Jun 30 2019 | n/a | n/a | -US$371m |
| Mar 31 2019 | n/a | n/a | -US$325m |
| Dec 31 2018 | US$5m | US$680k | -US$198m |
| Sep 30 2018 | n/a | n/a | -US$192m |
| Jun 30 2018 | n/a | n/a | -US$183m |
| Mar 31 2018 | n/a | n/a | -US$204m |
| Dec 31 2017 | US$7m | US$638k | -US$302m |
Compensatie versus markt: De totale vergoeding ($USD 13.08M ) Emil } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 6.54M ).
Compensatie versus inkomsten: De vergoeding van Emil is gestegen terwijl het bedrijf verliesgevend is.
CEO
Emil Kakkis (64 yo)
14.6yrs
Tenure
US$13,077,993
Compensatie
Dr. Emil D. Kakkis, M.D., Ph D., is Executive Director of Amlogenyx Inc. Dr. Kakkis has been a Director of Actio Biosciences Inc. since July 2024. He is Venture Advisor of Forge Life Science Partners.He i...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Founder | 14.6yrs | US$13.08m | 2.91% $ 126.8m | |
| Executive VP of Corporate Strategy & CFO | 1.1yrs | US$5.94m | 0.014% $ 596.3k | |
| Chief Legal Officer & Executive VP of Corporate Affairs | 8.4yrs | US$4.04m | 0.017% $ 723.2k | |
| Chief Quality Operations Officer & Executive VP of Translational Sciences | 9.3yrs | US$4.05m | 0.050% $ 2.2m | |
| Executive VP & Chief Commercial Officer | no data | US$4.07m | 0.025% $ 1.1m | |
| Senior VP | 10.8yrs | geen gegevens | 0.019% $ 840.4k | |
| Chief Human Resources Officer & Executive VP | 4.2yrs | geen gegevens | geen gegevens | |
| Chief Business Officer & Executive VP | 13yrs | US$2.46m | 0.23% $ 9.9m | |
| Senior Vice President of Business Development & Alliance Management | 6.7yrs | geen gegevens | geen gegevens | |
| Chief Technical Operations Officer and Executive VP of Gene Therapy Research & Development | 9.5yrs | US$4.24m | 0.044% $ 1.9m | |
| Senior Vice President of Corporate Strategy & Finance | no data | geen gegevens | geen gegevens | |
| Chief Medical Officer & Executive VP | 1.5yrs | geen gegevens | 0.020% $ 868.3k |
8.9yrs
Gemiddelde duur
58yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van RARE is doorgewinterd en ervaren (gemiddelde ambtstermijn van 8.9 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Founder | 14.6yrs | US$13.08m | 2.91% $ 126.8m | |
| Independent Non-Executive Chairman | 9.6yrs | US$499.89k | 0.023% $ 1.0m | |
| Independent Director | 10.8yrs | US$479.89k | 0.016% $ 701.8k | |
| Independent Director | 5.8yrs | US$466.89k | 0.016% $ 701.8k | |
| Independent Director | 7.6yrs | US$459.89k | 0.021% $ 932.0k | |
| Independent Director | 3.4yrs | US$469.39k | 0.0058% $ 252.4k | |
| Independent Director | 9.8yrs | US$482.39k | 0.023% $ 1.0m | |
| Independent Director | 2.6yrs | US$460.39k | 0.011% $ 499.6k |
8.6yrs
Gemiddelde duur
63yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van RARE wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.6 jaar).